Circulars

10 November 2026

Required Executive Procedures Regarding Circular No. (46/2026)

Reference: CIR-2026-00000208

Required Executive Procedures Regarding Circular No. (46/2026)

Dear Directors of Healthcare Facilities,

 

Greetings,

 

With reference to Emirates Drug Establishment Circular No. (46/2026) regarding the regulations governing the handling of peptide products and compounds, and within the framework of the DHA responsibilities for supervising healthcare facilities and monitoring their compliance with regulatory requirements, kindly take the following actions:

  1. Take the necessary immediate measures to ensure that no peptide products or compounds covered by the circular are used, prescribed, dispensed, or handled, and quarantine them immediately in accordance with the provisions of the circular.
  2. Prepare a comprehensive inventory of all peptide products and compounds covered by the circular and available at the facility, indicating their regulatory status, sources, and purposes of use, by completing the attached inventory forms and submitting them to the Department of Health no later than 5 December 2026 via email at DrugControl@dha.gov.ae.
  3. Review the clinical records of patients who have previously used the peptide pharmaceutical preparations covered by the circular, ensure appropriate medical follow-up, and provide suitable therapeutic alternatives when necessary.

 We emphasize the importance of complying with and implementing the above-mentioned measures within the specified timeframes. DHA will monitor healthcare facilities’ compliance with the requirements outlined in the circular during upcoming regulatory inspection visits, review the inventory lists and their status with the Emirates Drug Establishment, and follow up on the implementation of the necessary measures in accordance with approved procedures.

 

We appreciate your cooperation and commitment to regulatory requirements and patient safety.

 

Best regards,

Supporting Documents:

Peptides.xlsx:

View Document

تعميم رقم 46 - 2026 بشأن ضوابط التعامل مع المنتجات والمركبات الببتيدية_.pdf:

View Document